Accueil / Tag Archives: OSE Immunotherapeutics

Tag Archives: OSE Immunotherapeutics

ESSENTIEL – BIOTECHFINANCES N° 843 – 11/02/2019

Innobio, Gilead, Zimmer Biomet, MeiraGtX, Sanofi, OSE Immunotherapeutics, GenSight, Sophia Genetics, ’ARCH
Venture Partners, Hillhouse Capital, 6 Dimensions Capital, Celgene Corporation, NYC Life Sciences Fund Crossject, HiberCell, Medincell, Ge,oscience, Sparing Vision, Matwin, Meet2wn, Pharnext, Genomic Vision, Global Bioenergies, Hybrigenics, DMS, Valneva, Oncodesign, Gliocure, Median Technologies, Quantum Surgical, DTA Medical.

Plus »

AU SOMMAIRE DE BIOTECHFINANCES n° 843 – 11/02/2019

LA UNE PREMIER CLOSING À 135 M€ POUR INNOBIO ESSENTIEL : monde, coté, non coté Entreprises et organisations citées :  Innobio, Gilead, Zimmer Biomet, MeiraGtX, Sanofi, OSE Immunotherapeutics, GenSight, Sophia Genetics, ’ARCH Venture Partners, Hillhouse Capital, 6 Dimensions Capital, Celgene Corporation, NYC Life Sciences Fund Crossject,  HiberCell, Medincell, Ge,oscience, Sparing Vision, Matwin, Meet2wn, Pharnext, Genomic …

Plus »

OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences

OSE Immunotherapeutics — Monday, December 10th 2018 at 5:00pm UTC Data presented at the Annual World Congress of Digestive Disease in Rome, Nov. 30 – Dec. 2, and at the Antigen-Specific Immune Tolerance Europe Summit in London, Dec. 10 – 12 Presentations highlight OSE-127’s differentiated mechanism of action and significant …

Plus »

OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127

OSE Immunotherapeutics — Monday, November 26th 2018 at 5:00pm UTC NANTES, France, Nov. 26, 2018 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced authorization by Federal Agency for Medicines and Health Products (FAMH) and Belgian Ethics Committee to initiate a Phase 1 clinical trial of OSE-127, a …

Plus »

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer

OSE Immunotherapeutics — Tuesday, November 20th 2018 at 7:00am UTC The trial, sponsored and conducted by oncology group GERCOR, will be supported by Bristol-Myers Squibb and OSE Immunotherapeutics Pancreatic cancer is an indication with significant unmet need and represents an important new opportunity for Tedopi® clinical development Opening of Phase …

Plus »

OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

OSE Immunotherapeutics — Tuesday, October 30th 2018 at 5:00pm UTC Basel, Oct. 29-31, 2018 NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, Switzerland. Bernard Vanhove, chief operating officer and director …

Plus »

OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)

OSE Immunotherapeutics — Monday, October 29th 2018 at 6:00am UTC Full Antagonist Mechanism of Action Demonstrated In Vivo Long-term Control of Specific Memory T Cell Mediated Autoimmunity and Chronic Inflammation NANTES, France, Oct. 29, 2018 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced publication in Nature Communications …

Plus »

OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

OSE Immunotherapeutics — Friday, November 2nd 2018 at 7:00am UTC OSE to pursue clinical development of FR104 to treat autoimmune diseasesFR104’s good phase 1 clinical safety profile and first efficacy signal support phase 2 testing NANTES, France, Nov. 02, 2018 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire à la newsletter
Recevez chaque jour une newsletter riche d'informations.
2017 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.